Sage Therapeutics, Inc. (NASDAQ:SAGE) Holdings Raised by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. increased its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 5,420.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,806 shares of the biopharmaceutical company’s stock after purchasing an additional 21,411 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in Sage Therapeutics were worth $237,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. ProShare Advisors LLC lifted its holdings in shares of Sage Therapeutics by 9.0% in the first quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 1,130 shares during the period. State Board of Administration of Florida Retirement System lifted its stake in Sage Therapeutics by 9.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 16,644 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 1,480 shares during the last quarter. Quest Partners LLC boosted its holdings in Sage Therapeutics by 14.5% during the second quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 1,486 shares in the last quarter. Inspire Investing LLC boosted its holdings in Sage Therapeutics by 9.4% during the first quarter. Inspire Investing LLC now owns 19,234 shares of the biopharmaceutical company’s stock worth $360,000 after buying an additional 1,652 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Sage Therapeutics by 4.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,568 shares of the biopharmaceutical company’s stock worth $723,000 after buying an additional 1,693 shares during the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Trading Down 3.6 %

NASDAQ SAGE opened at $6.96 on Wednesday. Sage Therapeutics, Inc. has a 1-year low of $6.89 and a 1-year high of $28.26. The firm’s fifty day simple moving average is $8.42 and its 200-day simple moving average is $11.59. The company has a market capitalization of $424.91 million, a PE ratio of -0.83 and a beta of 0.91.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.02). The firm had revenue of $8.65 million during the quarter, compared to analyst estimates of $8.85 million. Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The business’s revenue for the quarter was up 249.8% on a year-over-year basis. During the same period in the previous year, the company earned ($2.68) earnings per share. As a group, analysts predict that Sage Therapeutics, Inc. will post -6.47 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SAGE. The Goldman Sachs Group reduced their price objective on Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating for the company in a research note on Friday, July 26th. TD Cowen lowered Sage Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the company from $16.00 to $10.00 in a research report on Tuesday, July 30th. Truist Financial reduced their price objective on shares of Sage Therapeutics from $18.00 to $13.00 and set a “hold” rating for the company in a research note on Wednesday, August 14th. HC Wainwright reiterated a “neutral” rating and issued a $25.00 target price on shares of Sage Therapeutics in a report on Friday, August 2nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research report on Thursday, August 1st. Two analysts have rated the stock with a sell rating, seventeen have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Sage Therapeutics presently has an average rating of “Hold” and an average target price of $16.06.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.